Hemovent expands Series A
Hemovent said today it received an undisclosed amount of funding as part of an oversubscribed Series A expansion round. The funds came from all existing investors, the Aachen, Germany-based company said, as well as newly invested 1st Capital Partner. Hemovent said that the funding comes shortly after it completed the 1st series of in vivo trials of its artificial lung technology platform which it is developing for a range of indications including extracorporeal CO2 removal and extracorporeal life support. “The fact that all Hemovent investors participated in this new round, and that 1st Capital Partner is an experienced life sciences investment firm known for investing sizable funds in both early-stage and follow-on rounds, bears strong testimony to the opportunity ahead of us as well as the efficient progress we have been able to make to date. Our investors understand Hemovent’s platform is positioned to disrupt a billion-dollar market. In vivo trials have already validated our platform’s superior blood-handling behavior and efficiency parameters compared to standard ECMO. We expect when Hemovent is available by mid-next year it will immediately drive ECMO usage not only for ECLS but also as an effective therapy for respiratory failure indications including ECCO2R protocols,” CEO Christof Lenz said in a prepared statement. Last February, Hemovent said it raised $6m in a Series A round to support its portable extra corporeal membrane oxygenat...
Conclusions Hypercapnia ameliorated acute cellular rejection in a rat lung transplantation model.
Max Olivares has a rare heart and lung condition, which requires a complex transplant operation.
Each individual BMI unit is an independent predictor of short- and long-term mortality after lung transplantation, and the patterns of this effect are not associated with predefined BMI categories.
This study represents the first linkage analysis between Pedimacs and Pediatric Heart Transplant Study databases to determine the effects of VAD course on post-transplant outcomes.
This article is protected by copyright. All rights reserved.
Acute cellular rejection(ACR) is a common complication in the first year after heart transplantation(HT). Routine surveillance for ACR is undertaken by endomyocardial biopsy(EMB). Measurement of Cardiac troponins(cTn) in serum is an established diagnostic test of cardiac myocyte injury. This systematic review aimed to determine if cTn measurement could be used to diagnose or exclude ACR.
By JAYSON CHUNG &AMANDA ZINK Currently, three South Korean medical institutions – Gachon University Gil Medical Center, Pusan National University Hospital and Konyang University Hospital – have implemented IBM’s Watson for Oncology artificial intelligence (AI) system. As IBM touts the Watson for Oncology AI’s to “[i]dentify, evaluate and compare treatment options” by understanding the longitudinal medical record and applying its training to each unique patient, questions regarding the status and liability of these AI machines have arisen. Given its ability to interpret data and p...
The McGowan Institute is developing an artificial lung for children and working on ways to keep organs for transplant longer.
Authors: Raffini L Abstract The evolution of devices for mechanical circulatory support (MCS), including ventricular assist devices (VADs) for patients with heart failure and extracorporeal membrane oxygenation (ECMO) for patients with acute cardiac or respiratory failure, has improved survival for subsets of critically ill children and adults. The devices are intricate and complex, allowing blood to bypass the heart or lungs (or both). As blood flows through these artificial devices, normal hemostasis is disrupted, coagulation is promoted, and in the absence of anticoagulation, a thrombus may form in the device, r...
Conclusions Lung retransplantation is a viable treatment option for CLAD after LTx. In this study, retransplantation patients were younger, had higher lung allocation scores, and were more likely to require cardiopulmonary bypass and postoperative extracorporeal membrane oxygenation support than primary LTx patients. Postoperative length of stay and short- and mid-term survival were comparable with those of primary LTx patients.